ADC Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Biopôle 3b, Epalinges, Vaud, 1066, Switz...Phone Number
+41 216530200Website
www.adctherapeutics.comRevenue
$79.2 MillionStock Symbol
ADCTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About ADC Therapeutics
ADC Therapeutics SA is a publicly traded, commercial-stage oncology biotechnology company headquartered in Epalinges, Switzerland, and listed on the NYSE under the ticker ADCT. Founded in 2011, the company is a global pioneer in the development of next-generation antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Its flagship product, ZYNLONTA (loncastuximab tesirine), is an FDA-approved CD19-directed ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ADC Therapeutics maintains an active clinical pipeline focused on expanding ZYNLONTA into earlier lines of therapy and additional lymphoma indications, alongside preclinical programs targeting a range of tumor antigens. The company operates globally with R&D in London, clinical and commercial operations in New Jersey, and chemistry, manufacturing, and controls (CMC) in the San Francisco Bay Area.Explore more
ADC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ADC Therapeutics
Product Launch: Get notified when ADC Therapeutics launches new products
Website visits: Recent activity has been detected on your website
ADC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if ADC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if ADC Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on ADC Therapeutics recently announced quarterly report
Check out if ADC Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once ADC Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined ADC Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
ADC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ADC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ADC Therapeutics.
ADC Therapeutics financials insights
Gather financial insights about ADC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$40M
2015
Unspecified
$80M
2016
Share Placement
$105M
Series D
$105M
2019
Series E
$303M
2020
Stock Offering
$267.6M
2022
Private Equity
$6.3M
Debt
$175M
2025
Stock/Share Issuance
$100M
ADC Therapeutics Tech Stack
A closer look at the technologies used by ADC Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Layoffs
Layoffs, Financial Planning, Pharmaceuticals, Clinical Operations, Finance, Financial Strategy
Project
reported that the overall response rate of 58.1% for ZYNLONTA plus rituximab versus 45.2% for R-GemOx, with a complete response rate of 39.5% versus 26.7%, and a median time to complete response of 49 days versus 65 days, favoring the ZYNLONTA plus rituximab arm.
Project
reported that duration was 9.2 months for ZYNLONTA plus rituximab versus 7.7 months for R-GemOx, with duration of complete response of 16.8 months versus 12.3 months, and a higher proportion of complete responses maintained at 24 months at 48.5% versus 16.7%.
Project
Clinical Operations
ADC Therapeutics News & Media
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of...ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details
ADC Therapeutics (ADCT) on Wednesday announced it would cut its global workforce by about 17% to focus on its ZYNLONTA franchise and regulatory and clinical milestones.At the time of writing, ADCT stock was down 2.6% during Wednesday’s premarket session.ADC Therapeutics said the reduction in workfo…ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of...INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding ADC Therapeutics
Sign Up For FreeTo access detailed company insights
ADC Therapeutics SA is a publicly traded, commercial-stage oncology biotechnology company headquartered in Epalinges, Switzerland, and listed on the NYSE under the ticker ADCT. Founded in 2011, the company is a global pioneer in the development of next-generation antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and soli... Read More
